Clinical trials: DM
Intermittent Explosive Disorder
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate AVP-786 for the treatment of Intermittent Explosive Disorder (IED).
- Trial name
- NCT03420222
- Testing
- AVP-786
- Where
- 9 sites in United States
- Volunteers
- 10 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Diabetes Mellitus, Type 2
Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day
Primary Objective: To evaluate the effect of prandial treatment adjustment, based on continuous blood glucose monitoring, on glucose control in type 2 diabetes patients who are not controlled by treatment with once daily basal…
- Trial name
- SeLan (NCT01234597)
- Testing
- INSULIN GLARGINE (HOE901), INSULIN GLULISINE (HMR1964)
- Where
- 11 sites in Israel
- Volunteers
- 219 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea
The purpose of this study is to provide an initial assessment of the safety, tolerability and efficacy of ISIS 113715 in combination with sulfonylurea in type 2 diabetes subjects.
- Trial name
- NCT00455598
- Testing
- ISIS 113715
- Where
- 39 sites in Poland, Romania and 1 more
- Volunteers
- 88 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in patients with advanced cancers - melanoma, lung, breast and glioblastoma multiforme (GBM) involving the CNS during…
- Trial name
- DM-CHOC-PEN (NCT02038218)
- Testing
- 4-Demethyl-4-cholestryloxycarbonylpenclomedine
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- DEKK-TEC, Inc.
Diabetes Mellitus Type II
20 Week Bridging Study in Type II DM
A multicenter, non-comparative, one arm, open, phase III study to evaluate the efficacy and safety of insulin glargine on subjects with Type 2 Diabetes Mellitus
- Trial name
- NCT00563225
- Testing
- Insulin Glargine
- Volunteers
- 90 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Primary Objective: To compare LixiLan to lixisenatide in glycated hemoglobin (HbA1c) change from baseline to Week 26 in patients with type 2 diabetes mellitus.
- Trial name
- LIXILAN JP-O1 (NCT02749890)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Lixisenatide (AVE0010), Oral anti-diabetic drugs
- Where
- 61 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Sanofi
Diabetes Mellitus Type 2
ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus
The purpose of this study is to evaluate whether a combination of pharmacist-delivered patient engagement techniques improves disease control and medication adherence among patients with poorly-controlled diabetes compared with…
- Trial name
- ENGAGE-DM (NCT02910089)
- Testing
- Shared Decision Making
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Agitation in Patients With Dementia of the Alzheimer's Type
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This was an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305.
- Trial name
- NCT02446132
- Testing
- AVP-786
- Where
- 227 sites in United States, Bulgaria and 8 more
- Volunteers
- 1,197 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Diabetes Mellitus, Type 2
RF Vapor Ablation Retreatment of Duodenal Mucosa in Non-responders With Type-2 Diabetes Mellitus
The purpose of this study is to test the hypothesis that re-treatment of the duodenal mucosa with RF vapor ablation will result in improvement in glycemic parameters, without complications (bleeding/ stricture / perforation)…
- Trial name
- NCT06724822
- Testing
- RF Vapor Ablation
- Where
- Chile
- Volunteers
- 12 people
- Sponsor
- Aqua Medical, Inc.
Type 2 Diabetes Mellitus
Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)
The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- NCT02831361
- Testing
- Gemigliptin, Metformin, Diet/exercise questionnaire
- Volunteers
- 290 people
- Sponsor
- LG Life Sciences
Myotonic Dystrophy 1, Myotonic Dystrophy 2
An Ambispective Natural History Study in Myotonic Dystrophy Patients Linking Retrospective Data Captured From the DM-Scope Registry With a Prospective 24-month Follow-up Period
This natural history observational study is being conducted to follow patients with DM1 or DM2 over a 2 year period to study the presence of myotonia, how it's perceived and its impact on patients quality of life.
- Trial name
- Track-DM (NCT07732439)
- Where
- 6 sites in France
- Volunteers
- 100 people
- Sponsor
- Lupin Ltd.
Obesity
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU)…
- Trial name
- NCT00603291
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 604 people
- Sponsor
- Eisai Inc.
Diabetes (DM), Diabetes Mellitus Type 2
Bridge Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone
This Phase 3 Bridge study is designed to evaluate the efficacy and safety of IN-B00009 Injection in Patients with T2DM Inadequately Controlled by Diet and Exercise Alone
- Trial name
- NCT07308184
- Testing
- IN-B00009
- Volunteers
- 110 people
- Sponsor
- HK inno.N Corporation
Type 2 Diabetes
Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)
The purpose of this investigation is to describe general safety profile of type II Diabetes Mellitus (DM) Japanese patients under exenatide therapy in real world medical practices
- Trial name
- NCT01817569
- Where
- 46 sites in Japan
- Volunteers
- 2,948 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily…
- Trial name
- OpT2mise (NCT01182493)
- Testing
- Insulin Pump (Medtronic Minimed Paradigm® VEO)
- Where
- 36 sites in United States, Austria and 11 more
- Volunteers
- 331 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Dyslipidemia
Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes
This study is to investigate correlation between Carotid Intima Media Thickness (cIMT) and several factors such as; hs C-reactive protein (CRP), HbA1c, lipid profile in Korean diabetic patients with atherosclerosis.
- Trial name
- ALTO (NCT01264263)
- Where
- 3 sites in South Korea
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Type 2 Diabetes, Diabetes (DM)
Detecting Type 2 Diabetes From Voice
The goal of this observational study is to learn if computer analysis of voice recordings can detect Type 2 diabetes in adults. The main questions it aims to answer are: Can advanced voice analysis accurately identify…
- Conditions
- Type 2 Diabetes, Diabetes (DM), T2DM, T2DM (Type 2 Diabetes Mellitus)
- Trial name
- NCT07421921
- Where
- United Kingdom
- Volunteers
- 7,319 people, healthy volunteers welcome
- Sponsor
- Thymia Limited
Type2diabetes
DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes
Key finding of DM Treatment with combination, A MuLticenter, Randomized, Parallel, Gathering Information of phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone add-on to Metformin and DPP-4…
- Trial name
- KLIMT (NCT06875193)
- Testing
- DW6012(Dasidiem tab. 10/100mg)
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Agitation in Patients With Dementia of the Alzheimer's Type
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with…
- Trial name
- NCT04464564
- Testing
- AVP-786
- Where
- 106 sites in United States, Belgium and 11 more
- Volunteers
- 241 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Revision Total Hip Arthroplasty, Primary Total Hip Arthroplasty
Retrospective Observational Cohort Study of SYMBOL CUP DM 2
This is a single-center retrospective observational cohort study of consecutively operated patients who underwent total hip arthroplasty (THA) with a SYMBOL CUP DMR HA or a SYMBOL CUP DM CEM hemispherical dual mobility acetabular…
- Trial name
- SYMCOR-2 (NCT04209426)
- Testing
- THA with SYMBOL CUP DMR HA, THA with SYMBOL CUP DM CEM
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Dedienne Sante S.A.S.